| Product | Code | ||
|---|---|---|---|
| Naratriptan hydrochloride | T6602 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| 8-pCPT-2-O-Me-cAMP-AM | T22536 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Fadrozole | T7197 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| DNP-PEG4-DBCO | T17839 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| SN50 | T12942 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Val-Cit-PAB-MMAE | T18867 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Acitretin sodium | T22548 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| A 53693 | T26419 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| MS432 | T13782 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| BMY-21502 | T30549 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Gelomulide A | TN5596 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| G3335 Acetate | T21598L | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Osalmid | T0353 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| PD158780 | T5410 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| O4I1 | T2439 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| UFP 803 acetate | TP2104L | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| RMM-46 | T26103 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| 5beta-Hydroxycostic acid | TN3140 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| CB2 receptor agonist 3 | T24097 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| WNK-IN-3 | T29160 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| 1,3,7-Trimethyluric acid | T19792 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| R214127 | T34243 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| Dihydroperaksine | TN3860 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| NSC 66811 | T21578 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
| NeuroSensor 521 | T33655 | 1mg/5mg/10mg/25mg/50mg/100mg |
Contact us |
Nvigen
NVIGEN is a nanotechnology empowered personalized medicine innovator.
Our pipeline of visionary solutions stems from our innovative nanomedicine platform. We are focusing on the development of a comprehensive circulating bio-marker biopsy technology, NVIGEN X™, to predict cancer recurrence at the earliest possible time and guide the most effective personalized therapy.
NVIGEN X™ is enabled by the state-of-the-art molecularly engineered nanoparticles, MagVigen™ and MyQuVigen™, to efficiently capture and identify molecular information from proteins, cells and nucleic acids. We are developing NVIGEN X™ into accurate, automated and FDA approved clinical instruments and reagent kits deployable at hundreds and thousands of hospitals, turning fatal cancers into manageable diseases.
¿Más información? Contáctenos por correo electrónico info@divbio.es